Concepedia

Daniel P. Mould

DP

Statistics

Publications

8

Citations

501

H-Index

8

Active since

2013

Affiliations

Cancer Research UK Manchester Institute(Current)

University of Manchester

Beactica (Sweden)

Cancer Research UK

Daniel P. Mould is an author at Cancer Research UK Manchester Institute specializing in pharmacology, medicinal chemistry, and drug discovery.

ORCID

Publications per year

2013–2018

8

Publications

8

Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia

Alba Maiqués-Díaz, Gary J. Spencer, James T. Lynch et al. · Cell Reports · 2018 · 222 citations · Full text

, , +17

Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments

James R. Hitchin, Julian Blagg, Rosemary Burke et al. · MedChemComm · 2013 · 65 citations

, , +17

Toxoflavins and Deazaflavins as the First Reported Selective Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase II

Ali Raoof, Paul Depledge, Niall M. Hamilton et al. · Journal of Medicinal Chemistry · 2013 · 61 citations · Full text

, , +15

Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1

Daniel P. Mould, Cristina Alli, Ulf Bremberg et al. · Journal of Medicinal Chemistry · 2017 · 48 citations · Full text

, , +13

The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity

Rebecca Newton, Katherine A. Bowler, Emily M. Burns et al. · European Journal of Medicinal Chemistry · 2016 · 39 citations · Full text

, , +13

1–5 of 8